Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin

Besselaar, A.M.H.P. van den; Neuteboom, J.; Bertina, R. M.

doi:10.1097/00001721-199304060-00006

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Activated partial thromboplastin time (aPTT): activated partial thromboplastin time (Instrumentation Laboratory) was determined on a coagulation analyser (ACL® 6000, Instrumentation Laboratory, Bedford, MA, USA). This test was applied to plasma samples as described previously (16)(17)(18).…”

Section: Coagulation Assaysmentioning

confidence: 99%

Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients

Bluecher¹,

Santos²,

Ferreiròs³

et al. 2017

Thromb Haemost

View full text Add to dashboard Cite

Reliable detection of anticoagulation status in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) is challenging but of importance especially in the emergency setting. This study evaluated the potential of a whole-blood clotting time assay based on Surface Acoustic Waves (SAW-CT) in stroke-patients. The SAW-technology was used for quick and homogenous recalcification of whole blood inducing a surface-activated clotting reaction quantified and visualised by real-time fluorescence microscopy with automatic imaging processing. In 20 stroke or transient ischaemic attack (TIA)-patients taking NOACs kinetics of SAW-CT were assessed and correlated to other coagulation parameters (PT, aPTT) and NOAC-plasma concentration measured by tandem mass spectrometry (LC-MS/MS). In 225 emergency patients with suspicion of acute stroke or TIA, SAW-CT values were assessed. Mean (± SD) SAW-CT in non-anticoagulated stroke patients (n=180) was 124 s (± 21). In patients on dabigatran or rivaroxaban, SAW-CT values were significantly higher 2 and 8 hours (h) after intake rising up to 267 seconds (s) (dabigatran, 2 h after intake) and 250 s (rivaroxaban, 8 h after intake). In patients on apixaban, SAW-CT values were only moderately increased 2 h after intake (SAW-CT 153 s). In emergency patients, SAW-CT values were significantly higher in NOAC and vitamin K antagonist (VKA)-treated as compared to non-anticoagulated patients. In conclusion, the SAW-CT assay is capable to monitor anticoagulant level and effect in patients receiving dabigatran, rivaroxaban and the VKA phenprocoumon. It has a limited sensitivity for apixaban-detection. If specific SAW-CT results were used as cut-offs, SAW-CT yields high diagnostic accuracy to exclude relevant rivaroxaban and dabigatran concentrations in stroke-patients.

show abstract

Section: Coagulation Assaysmentioning

confidence: 99%

Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients

Bluecher¹,

Santos²,

Ferreiròs³

et al. 2017

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…HemosIL ® APTT-SP (liquid) was used to determine the aPTT value, as described by Van de Bresselaar [ 100 , 101 ]. The aPTT test utilizes a contact activator (a colloidal silica dispersion with synthetic phospholipids, buffer and a preservative) that stimulates factor XIIa production.…”

Section: Methodsmentioning

confidence: 99%

High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies

Bernal

Peláez

Alías

et al. 2021

IJMS

View full text Add to dashboard Cite

Factor V is an essential clotting factor that plays a key role in the blood coagulation cascade on account of its procoagulant and anticoagulant activity. Eighty percent of circulating factor V is produced in the liver and the remaining 20% originates in the α-granules of platelets. In humans, the factor V gene is about 80 kb in size; it is located on chromosome 1q24.2, and its cDNA is 6914 bp in length. Furthermore, nearly 190 mutations have been reported in the gene. Factor V deficiency is an autosomal recessive coagulation disorder associated with mutations in the factor V gene. This hereditary coagulation disorder is clinically characterized by a heterogeneous spectrum of hemorrhagic manifestations ranging from mucosal or soft-tissue bleeds to potentially fatal hemorrhages. Current treatment of this condition consists in the administration of fresh frozen plasma and platelet concentrates. This article describes the cases of two patients with severe factor V deficiency, and of their parents. A high level of mutational heterogeneity of factor V gene was identified, nonsense mutations, frameshift mutations, missense changes, synonymous sequence variants and intronic changes. These findings prompted the identification of a new mutation in the human factor V gene, designated as Jaén-1, which is capable of altering the procoagulant function of factor V. In addition, an update is provided on the prospects for the treatment of factor V deficiency on the basis of yet-to-be-developed recombinant products or advanced gene and cell therapies that could potentially correct this hereditary disorder.

show abstract

“…Activated partial thromboplastin time (aPTT): activated partial thromboplastin time (aPTT-SP-Liquid, Instrumentation Laboratory, Munich, Germany, normal range 22-26 s) was determined on a coagulation analyzer (ACL V R 6000, Instrumentation Laboratory; Milan, Italy) as has previously been described. [13][14][15] This test was applied to plasma samples containing UFH and direct thrombin inhibitors.…”

Section: Practical Test On Patient Bloodmentioning

confidence: 99%

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

et al. 2013

View full text Add to dashboard Cite

A universal coagulation test that reliably detects prolonged coagulation time in patients, irrespective of the anticoagulant administered, has not been available to date. An easily miniaturised, novel μ-fluidic universal coagulation test employing surface acoustic waves (SAW) is presented here. SAW was employed to instantly mix and recalcify 6 μl citrated whole blood and image correlation analysis was used to quantify clot formation kinetics. The detection of clinically relevant anticoagulant dosing with old anticoagulants (unfractionated heparin, argatroban) and new anticoagulants (dabigatran, rivaroxaban) has been tested and compared to standard plasma coagulation assays. The applicability of this novel method has been confirmed in a small patient population. Coagulation was dose-proportionally prolonged with heparin, argatroban, dabigatran, and rivaroxaban, comparable to standard tests. Aspirin and clopidogrel did not interfere with the SAW-induced clotting time (SAW-CT), whereas the strong GPIIb/IIIa-inhibitor abciximab did interfere. Preliminary clinical data prove the suitability of the SAW-CT in patients being treated with warfarin, rivaroxaban, or dabigatran. The system principally allows assessment of whole blood coagulation in humans in a point-of-care setting. This method could be used in stroke units, emergency vehicles, general and intensive care wards, as well as for laboratory and home testing of coagulation.

show abstract

Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin

Cited by 5 publications

References 0 publications

Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients

Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients

High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

Contact Info

Product

Resources

About